Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation.
Launched by TAIPEI MEDICAL UNIVERSITY · Aug 29, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of three supplements—UC-II, glucosamine, and curcumin—on people who experience chronic knee pain and inflammation. The goal is to see if these supplements can help reduce pain and improve overall knee health. The trial is currently looking for participants aged between 73 and 255 years, and anyone with knee pain might be eligible to join. However, individuals with severe health issues, such as major heart or kidney diseases, or those who take certain long-term medications, may not qualify.
If you decide to participate, you can expect to take the supplements being studied and share your experiences regarding any changes in your knee pain and inflammation over time. This trial is an opportunity to contribute to research that could help others with similar issues, while also potentially finding relief for your own knee discomfort. Remember, it’s important to discuss any questions or concerns with your healthcare provider before joining the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Knee plain
- Exclusion Criteria:
- • Severe diseases of the heart, liver, kidneys, endocrine system, and other organs
- • Long-term use of medication
- • Infection, hypertension, diabetes, cerebrovascular disease, heart disease, liver disease, kidney disease, gastrointestinal disease
- • Allergy to this product
About Taipei Medical University
Taipei Medical University (TMU) is a leading educational and research institution located in Taipei, Taiwan, dedicated to advancing health sciences and clinical research. Established with a focus on fostering innovation in medical education, TMU integrates comprehensive clinical training with rigorous research methodologies. The university is committed to improving patient outcomes through a strong emphasis on translational medicine and interdisciplinary collaboration. TMU's clinical trial initiatives are designed to explore new treatments and therapies, contributing to the global body of medical knowledge while adhering to the highest ethical standards and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported